Celon Pharma S.A.

zł 16.30As of Sun 8 Nov 2026, 12:00 UTC
WSE:CLNHealthcare
Country Poland
PE (Fwd) •••
TSR 10Y CAGR (3.57%)
Div yield —
ROE 24.17%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.60
PE TTM 7.989
TSR TTM (24.36%)
Mkt cap zł 877.9M
ROIC (0.62%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
zł 16
1.06%
(93.36%)
Hold 12|11|4|4|3
4Q25
1Q26
2Q26
3Q26
Earnings per sharezł
0.22
0.24
0.24
0.27
11.82%
16.98%
15.80%
19.54%
Revenuezł M
104.7
103.3
107.8
108.5
4.80%
1.73%
3.12%
0.67%
Peers (US$221.7M)
Cap (US$)
PE
141.7M
—
96.40M
—
11.79M
9.105x
Capital
TTM
5Y
10Y
Leveragex
1.760
0.136
0.094
EBIT/Intx
0.149
0.323
0.323
Own earn%
(239.51)
8.11
10.15
Sh yield%
40.78
22.53
25.65
Owners
Insiders/Inst%
14.35
46.67
Short interest%
2.52
SBC / revenue%
5.91
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
8–13
$1 testx
—
Incr. ROIC%
5